Acute myeloid leukemia (AML) may develop de novo or secondarily to myelodysplastic syndrome (MDS). Although the clinical outcome of MDS-related AML is worse than that of de novo AML, it is not easy to differentiate between these two clinical courses without a record of prior MDS. Large-scale profiling of gene expression by DNA microarray analysis is a promising approach with which to identify molecular markers specific to de novo or MDS-related AML. This approach has now been adopted with AC133-positive hematopoietic stem cell-like fractions purified from 10 individuals, each with either de novo or MDS-related AML of the M2 subtype. Sets of genes whose activity was associated with either disease course were identified. Furthermore, on the basis of the expression profiles of these genes, it was possible to predict correctly the clinical diagnosis for 17 (85%) of the 20 cases in a cross-validation trial. Similarly, different sets of genes were identified whose expression level was associated with clinical outcome after induction chemotherapy. These data suggest that, at least in terms of gene expression profiles, de novo AML and MDS-related AML are distinct clinical entities.
Introduction
Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells (HSCs) that affects mostly the elderly (median age of 70 years). MDS is characterized by two clinical manifestations: (i) cytopenia in peripheral blood despite hyperor normal cellularity in bone marrow (BM), a condition referred to as ineffective hematopoiesis, and (ii) dysplastic changes in blood cells. 1 It is a multistage syndrome, the early stages of which are termed refractory anemia (RA), RA with ringed sideroblasts, or refractory cytopenia with multilineage dysplasia (RCMD). 2 Between 10 and 50% of cases of MDS, especially those associated with unfavorable chromosomal abnormalities, eventually undergo malignant transformation into MDS-related acute myeloid leukemia (AML), the outcome of which is poor. 3, 4 The blasts of individuals with MDS are, in general, refractory to chemotherapeutic agents, and a cure for this condition is rarely achievable except in cases in which allogeneic BM transplantation is applicable. It is therefore clinically important to be able to differentiate between individuals with de novo AML and those with MDS-related AML.
However, such differentiation is not always an easy task. Some types of dysplasia are apparent even in BM cells of healthy people and such changes become more prominent in the elderly. 5, 6 Chromosomal anomalies often associated with MDS, including those affecting chromosomes 5 and 7, are also manifest in some de novo AML blasts and indeed are an indicator of poor prognosis in AML patients. It is therefore often difficult to diagnose correctly elderly individuals with AML and dysplastic changes if knowledge of a preceding history of MDS is not available.
Complicating issues even further, certain cases of de novo AML (with the absence of prior MDS history or anticancer treatment) may be associated with prominent blood cell dysplasia. The recent proposal for AML classification by the World Health Organization stipulates that individuals with AML and dysplastic cells be diagnosed with AML with multilineage dysplasia (AML-MLD), irrespective of whether the AML is de novo or secondary to MDS. 7 It remains to be determined whether AML-MLD is an amalgamation of clinical entities with distinct mechanisms as well as prognoses.
DNA microarray analysis allows the monitoring of the levels of expression of thousands of genes simultaneously 8 and may therefore help to identify molecular markers that differentiate de novo AML from MDS-related AML. However, a simple comparison of BM mononuclear cells (MNCs) between these two conditions may be problematic. The cell composition of BM MNCs differs markedly among individuals. Differences in the gene expression profiles between BM MNCs from a given pair of individuals may thus reflect these differences in cell composition. The elimination of such pseudopositive and pseudonegative data necessitates the purification of background-matched cell fractions from the clinical specimens before microarray analysis.
Given that MDS results from a transformation of HSC clones, HSCs are an appropriate target for purification and gene expression analysis. With the use of an affinity purification procedure based on the HSC-specific surface protein AC133, 9 we have therefore initiated a nationwide project aimed at the purification and storage of HSC-like fractions from individuals with leukemia and related disorders in Japan. To date, more than 400 purified cell fractions have been deposited in this 'Blast Bank. ' To further reduce the influence of differentiation commitment of blasts toward certain lineages, we selected for the present study only those Blast Bank samples with the same phenotype, the M2 subtype according to the classification of the FrenchAmerican-British (FAB) Cooperative Group. 10 We thus characterized the expression profiles of 412 000 genes in AC133 þ Blast Bank samples from 10 patients with de novo AML of the M2 subtype as well as from 10 individuals with MDS-related AML of the M2 subtype. Comparison of the microarray data revealed gene markers of potential clinical utility for the diagnosis and prediction of response to chemotherapy.
Materials and methods

Purification of AC133
þ cells BM aspirates were obtained from subjects with written informed consent and the AC133 þ HSC-like fraction was purified from each specimen as described previously. 11, 12 In brief, MNCs were isolated by Ficoll-Hypaque density gradient centrifugation, labeled with AC133 MicroBeads (Miltenyi Biotec, Auburn, CA, USA), and subjected to chromatography on a mini-MACS magnetic cell separation column (Miltenyi Biotec). Enrichment of the HSC-like fraction was evaluated by subjecting portions of the MNC and AC133 þ cell preparations either to staining with Wright-Giemsa solution or to analysis of the expression of CD34, CD38, and AC133 by flow cytometry (FACScan; Becton Dickinson, Mountain View, CA, USA). In most instances, the CD34 high CD38 low fraction constituted 490% of the eluate of the affinity column.
DNA microarray analysis
Total RNA was extracted from the AC133 þ cell preparations by the acid guanidinium method and was subjected to two rounds of amplification with T7 RNA polymerase as described. 13 A total of 1 mg of the amplified cRNA was then converted to doublestranded cDNA, which was used to prepare biotin-labeled cRNA for hybridization with GeneChip HGU95Av2 microarrays (Affymetrix, Santa Clara, CA, USA) harboring oligonucleotides corresponding to a total of 12 625 genes. Hybridization, washing, and detection of signals on the arrays were performed with the GeneChip system (Affymetrix). To evaluate the fidelity of the RNA amplification procedure, we subjected total RNA and cRNA after one (aRNA1) or two (aRNA2) rounds of amplification from the same patient sample independently to the hybridization with the GeneChip system. The resulting expression intensities yielded Pearson's correlation coefficients of 0.807 for total RNA and aRNA1 and of 0.931 for aRNA1 and aRNA2. In the same experiments, the ratio of the number for genes with 'Present' call and those with 'Absent' call was calculated to be 0.261 for total RNA, 0.303 for aRNA1, and 0.171 for aRNA2.
Statistical analysis
The fluorescence intensity for each gene was normalized relative to the fluorescence value for the 50th percentile gene with a 'Present' or 'Marginal' call (Microarray Suite 4.0, Affymetrix) in each hybridization. Hierarchical clustering of the data set and isolation of diagnosis-related genes were performed with GeneSpring 5.0.3 software (Silicon Genetics, Redwood, CA, USA). All raw array data as well as details of the genes shown in the figures are available as supplementary information at the Leukemia web site. The raw array data will also be accessible from the Array-Express web site (http:// www.ebi.ac.uk/arrayexpress).
Real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis
Portions of nonamplified cDNA were subjected to PCR with a QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA, USA). The amplification protocol comprised incubations at 941C for 15 s, 601C for 30 s, and 721C for 60 s. The annealing temperature was raised up to 631C only for the amplification of the topoisomerase IIb (TOPIIB) cDNA. Incorporation of the SYBR Green dye into PCR products was monitored in real time with an ABI PRISM 7700 sequence detection system (PE Applied Biosystems, Foster City, CA, USA), thereby allowing determination of the threshold cycle (C T ) at which exponential amplification of PCR products begins. The C T values for cDNAs corresponding to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), DLK and TOPIIB genes were used to calculate the abundance of DLK or TOPIIB mRNA relative to that of GAPDH mRNA. The oligonucleotide primers for PCR were 5 0 -GTCAGTGGTGGACCTGACCT-3 
Results
Purification of Blast Bank cells
To demonstrate the utility of the Blast Bank strategy, we previously compared the expression of the CD34 gene between BM MNCs and AC133
þ cells by microarray analysis. 11 The expression level of the gene was 519 and 42 322 arbitrary units (U) in a healthy volunteer and a patient with MDS-related AML, respectively, in the analysis of BM MNCs. However, in the analysis of AC133 þ cells from the same two individuals, the expression levels were 6 749 546 and 5 543 512 U in the volunteer and patient, respectively. The apparent induction of the CD34 gene in the MNCs of the patient thus actually reflected the expansion of the immature blasts expressing this gene.
From our Blast Bank depository, we selected 20 specimens derived from individuals with AML of the FAB M2 subtype, half of them (n ¼ 10) with de novo AML and the other half (n ¼ 10) with MDS-related AML. The clinical characteristics of the 20 patients are summarized in Table 1 . The M2-specific karyotype anomaly, t(8;21), was apparent in five of the de novo AML patients, but in none of those with MDS-related AML. All patients were treated with anthracyclin-and/or cytarabinebased regimens, with most of those with MDS-related AML being refractory to treatment.
For the expression profiling of AC133 þ cells to be meaningful, such fractions should contain substantial numbers of leukemic clones. We were able to purify 41 Â 10 6 AC133 þ cells from the BM MNCs of our patients with AML M2, whereas the yield of AC133 þ cells was only 1000-5000 cells from similar starting numbers of BM MNCs obtained from healthy volunteers (data not shown). The purified HSC-like fractions from individuals with AML thus likely consist predominantly of leukemic HSC-like cells. This conclusion was supported by our observation that, for one individual with MDS-related leukemia, fluorescence in situ hybridization analysis revealed a À5q anomaly in only 54% of BM MNCs but in 96% of the corresponding purified AC133 þ cells (data not shown).
Transcriptome of AML M2 blasts
From the expression data obtained for the 412 000 human genes in the 20 samples analyzed, we first selected genes whose expression received the 'Present' call from the Microarray Suite 4.0 software in at least 10% of the samples, in order to exclude genes that were virtually silent transcriptionally. A total of 6672 genes passed this 'selection window', and their expression profiles in the 20 samples are shown in Figure 1a as a dendrogram, or 'gene tree', in which genes with similar expression profiles (assessed by standard correlation) among the samples are clustered near each other. Clusters of genes that were expressed preferentially in either the de novo AML blasts or the MDS-related AML blasts were thus revealed. The genes preferentially expressed in the MDS-related AML blasts were expressed at a substantial level in the blasts from only one (AML-1) of the patients with de novo AML.
To evaluate statistically the similarity of the overall gene expression profiles among the 20 samples, we generated another dendrogram, a 'patient tree,' by the two-way clustering method 14 with a separation ratio of 1.0 (Figure 1b) . The samples did not cluster into two major disease-specific branches; rather, de novo AML and MDS-related AML cases were mixed in several branches.
Identification of disease-associated genes
To identify genes whose expression might allow differentiation between de novo AML and MDS-related AML, we first examined those whose expression level differed significantly between the two groups of samples (Welch ANOVA test, Po0.01). A total of 574 such genes were identified. Most of these genes, however, were expressed at a low level in both types of specimens, rendering their utility as diagnostic markers uncertain. From these 574 genes, we therefore selected those whose mean expression intensity differed by X5.0 U between the two groups. The resulting 57 'disease-associated' genes are shown in a gene-tree format in Figure 2a ; 52 of these genes were specific to MDS-related AML and the remaining five were specific to de novo AML. The former group of genes included those for proteins important in regulation of the cell cycle (cyclin D3, GenBank accession number M92287; cyclin I, D50310; CDC10, S72008), in protein synthesis (elongation factor 1a, J04617; eIF4, D30655; elongation factor 1g-related protein, M55409; elongation factor 2, Z11692; eIF3 p47 subunit, U94855; elongation factor 1a-2, X70940; ribosomal protein S19, M81757; ribosomal protein S4, M58458; ribosomal protein S6, X67309), and in transcriptional regulation (CtBP, U37408; ERF-2, X78992; SP1, X68194). We next performed two-way clustering analysis of the 20 patients based on the expression levels of such 57 disease-associated genes (Figure 2b ). The patients clustered into two major branches, one containing only those with de novo AML and the other containing mostly those with MDS-related AML.
We also performed 'class prediction' analysis for the samples with GeneSpring software and with the 57 disease-associated genes as the 'class predictor' (http://www.silicongenetics.com/ Support/GeneSpring/GSnotes/class_prediction.pdf). In a crossvalidation ('drop-one-out') format, the 'k-nearest-neighbor' samples were counted in Euclidean distance for a 'dropped' sample, and the proportion of neighbor samples from each class was used to calculate the prediction P-value for each class (de novo AML or MDS-related AML). The resulting class predictions with a P-value ratio of o0.2 were determined to be significant. The disease prediction matched the clinical diagnosis for 17 
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Prediction of chemosensitivity
Seven of the patients with de novo AML and one patient with MDS-related AML (the CR group) underwent complete remission (CR) after the first induction chemotherapy, whereas three patients with de novo AML and nine patients with MDS-related AML (the Failure group) did not exhibit a sufficient reduction in the number of immature blasts in their BM in response to such treatment ( Table 1 ). Given that all Blast Bank samples in this study were obtained prior to chemotherapy, we next examined whether it was possible to predict treatment outcome on the basis of the gene expression profiles of the blasts. For this purpose, we first selected from the 6672 genes expressed in the AC133 þ cells of the various patients those whose expression levels differed significantly between the CR and Failure groups (Welch ANOVA, Po0.01). The resulting 1353 genes were then examined for those whose mean expression level differed by X5.0 U between the two groups. A total of 37 'outcome-associated' genes were so identified, 33 of which were preferentially expressed in the Failure group and the remaining four of which were expressed selectively in the CR group (Figure 3a) . Unexpectedly, only 16 genes were common to both the disease-and outcomeassociated genes.
The genes associated with treatment failure included those for the transcription factor c-FOS (GenBank accession number, V01512), TOPIIB (X68060), INT6 (U62962), and sorting nexin 3 (AF034546). Topoisomerase is a target for anticancer drugs, such as etoposide, that are routinely used in the current treatment of AML. 15 A high level of TOPIIB expression might therefore contribute to drug resistance in the Failure group. To confirm the outcome-dependent expression of TOPIIB gene, we examined the mRNA level of TOPIIB by the quantitative RT-PCR analysis. As shown in Figure 3b , TOPIIB mRNA was abundant only in the leukemic blasts isolated from individuals with drugresistant AML.
Two-way clustering analysis based on the expression profiles of the 37 outcome-associated genes yielded two major branches: one containing all eight samples in the CR group and two Failure samples, and the other containing the remaining 10 samples in the Failure group (Figure 3c) . We also performed class prediction analysis with the 37 outcome-associated genes as we did with the disease-associated genes. The clinical response of 15 (75%) of the 20 cases was successfully predicted, that of three cases was not predictable, and that of the remaining two cases was predicted incorrectly (Table 3) .
Identification of single gene markers for chemosensitivity
The gene sets identified in Figures 2a and 3a may represent candidate genes for the construction of custom-made DNA microarrays for disease diagnosis and prediction of clinical outcome, respectively. Given that the availability of DNA microarray systems is still limited in hospitals, however, it would be beneficial to identify a single gene whose expression (at the mRNA or protein level) could be used as a reliable marker for such purposes. For example, it would be useful to be able to predict the drug sensitivity of leukemic blasts by flow cytometric analysis of a cell surface protein. It is unlikely, however, that determination of the expression of any single gene will allow correct diagnosis or prediction of drug sensitivity for all samples. We therefore attempted to identify individual genes whose high expression level might be sufficient to predict drug resistance, but the absence of which may not necessarily imply drug sensitivity. Such predictor genes would thus be inactive in leukemic blasts from all drug-sensitive patients but be active in samples from at least some proportion of drug-resistant individuals. Table 3 Prediction of response to chemotherapy þ blasts. Complementary DNA was prepared from the AML M2 blasts of the CR and Failure groups and was subjected to real-time PCR analysis with primers specific for the TOPIIB or GAPDH genes. The ratio of the abundance of TOPIIB mRNA to that of GAPDH mRNA was calculated as 2 n , where n is the C T value for GAPDH cDNA minus the C T value for TOPIIB cDNA. (c) Two-way clustering analysis of the 20 samples based on the expression levels of the outcome-associated genes. CR and Failure samples are shown in green and purple, respectively.
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We first calculated the mean expression levels of each of the 6672 expressed genes in both the CR and Failure groups. Then, with the use of the GeneSpring software, we searched for genes whose expression profiles were significantly similar, with a minimum correlation of 0.95, to that of a hypothetical 'Failurespecific gene' with a mean expression level of 0.0 U in the CR group and of 100.0 U in the Failure group. From the 2354 such genes identified, we then selected those whose expression value was both o3.0 U in all CR samples and X10.0 U in at least one of the Failure samples. A total of 42 genes was thus shown to be 'Failure specific' (Figure 4a ), of which we examined those with the fewest false-positive results (while allowing false-negative ones). The high level of expression of such genes in leukemic blasts would thus be predictive of treatment failure.
Among these genes was that for Delta-like (DLK), 16 a membrane protein that is thought to support the self-renewal of HSCs. With a cDNA microarray analysis of Blast Bank samples, we previously showed that DLK was transcriptionally active in the AC133 þ cells of individuals with MDS-related leukemia but not in those of patients with de novo AML.
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Given the substantial overlap of the Failure group with the MDSrelated AML group as well as the limited number of samples analyzed in the present study, it remains to be determined whether a high level of DLK expression is related to a specific disease type (MDS-related AML) or to chemosensitivity (treatment failure). However, independent analyses with distinct types of microarray (cDNA array and GeneChip) indicate that DLK is specifically activated in the blasts from individuals with overlapping subgroups of leukemia.
To confirm the GeneChip data, we determined the amount of DLK mRNA relative to that of GAPDH mRNA in the Blast Bank samples analyzed in the present study (Figure 4b ). The relative abundance of DLK mRNA was significantly correlated with the expression intensity of DLK in the GeneChip analysis (r ¼ 0.745, P ¼ 0.0016).
Discussion
We have compared the gene expression profiles of AC133 þ cells from individuals with two distinct clinical courses of the M2 subtype of AML. Purification of the AC133 þ leukemic stem cells from these individuals allowed us to match the specimens as closely as possible prior to microarray analysis. Our study was thus designed to address the question of whether de novo AML is a distinct clinical entity from MDS-related AML, and, if so, how distinct?
The overall gene expression profiles did not clearly separate the samples into two major branches corresponding to de novo and MDS-related AML. However, two-way clustering analysis of the disease-associated genes resulted in separation of the samples into two groups that closely mirrored the clinical diagnosis. Many of the genes associated with MDS-related AML likely provide growth-promoting or antiapoptotic activities in the MDS blasts. The increased expression levels of genes encoding cyclins, molecules important for protein synthesis, and oncoproteins thus indicate that the proliferative potential of MDS blasts is greater than that of de novo AML blasts. A reduced expression level of the gene for the proapoptotic protein BAX 17 in the MDS blasts is also consistent with this notion. The relatively high accuracy of the prediction of clinical diagnosis on the basis of the expression profiles of the disease-associated genes suggests that the products of these genes may play important roles in the pathogenesis.
We also attempted to predict the clinical outcome of the first induction chemotherapy in our study subjects. The genes associated with chemoresistance included those for transcription factors or cofactors such as c-FOS, OZF, SP1, INT6, and ELE1, many of which are implicated in oncogenesis. [18] [19] [20] [21] [22] Furthermore, the outcome-associated genes included those for proteins, such as TOPIIB and RNA helicases (DDX17 and DDX3Y), 23 involved in the winding or unwinding of nucleotide strands. Altered expression of these proteins might be linked directly to resistance to certain types of anticancer drugs.
Finally, we attempted to identify single gene markers able to predict chemoresistance of leukemic blasts. Given that the Failure group includes samples with different karyotypic anomalies, it might be expected that the mechanism of drug resistance of these samples exhibits similar heterogeneity. We therefore searched for genes that were silent transcriptionally in all samples of the CR group but were active in at least some of the samples in the Failure group.
Interestingly, out of the 42 'failure-specific' genes in Figure 4a , five genes encode for chemokines or chemokine receptors, such as proplatelet basic protein (GenBank accession number M54995) or CXC chemokine ligand 7, platelet factor 4 (M25897) or CXC chemokine ligand 4, interleukin 8 (IL8; M17017), chemokine CXC motif ligand 2 (M36820), and chemokine CX3C motif receptor 1 (U20350). Chemokines are a group of small proteins that play a pivotal role in the regulation of the immune system and of cell trafficking as well. Additionally, chemokines can exert pleiotropic effects on target cells, such as mitosis, homing, and even protection against chemotherapeutic reagents. A CC motif chemokine, CCL21, can inhibit, for instance, apoptosis induced by Ara-C. 24 Therefore, it would be possible that chemokine-mediated cell signaling helps to provide drug resistance to the leukemic blasts in our study. Given the high serum levels of IL8 protein in patients with AML and MDS, 25 activation of chemokine/chemokine receptor systems is likely to be relevant to the pathophysiology of leukemic disorders.
Certain types of transcriptional factors and/or their regulators are also activated transcriptionally in the drug-resistant leukemic blasts, including NMYC (GenBank accession number Y00664), basic helix-loop-helix domain containing class B2 (BHLHB2; AB004066), ID1 (X77956), ERG1 (M21535), and c-FOS. Additionally activated were the genes for nuclear proteins, that is, nuclear matrix protein NXP-2 (D50926), Wilms' tumor 1-associated protein 1 (WTAP; X84373), and nuclear receptor interacting protein 1 (NRIP1; X84373). NYMC, ERG1, and c-FOS all mediate mitotic signaling, and ID1 is known to inhibit cell differentiation. WTAP 26 and NRIP1 27 regulate the activity of WT1 and hormone receptors, respectively. Therefore, these gene products may be directly involved in the regulation of cell proliferation and differentiation process.
Conclusion
By narrowing the window of sample selection both to the same FAB subtype of de novo and MDS-related AML and to the same level of cell differentiation (as reflected by AC133 expression), we should have minimized population-shift effects that seriously hamper the ability to draw meaningful conclusions from microarray data. Further increases in the number of samples analyzed as well as in the number of genes on the arrays should help to pinpoint genes whose expression levels provide clinically useful information and make it possible to construct custom-made microarrays for the diagnosis of leukemias and the prediction of treatment outcome.
